Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20165789 | 0.91 | PTGS2 (0.31) | PTGS2PTGS1 | |
| SCHEMBL29873709 | 0.91 | PTGS2 (0.31) | PTGS2PTGS1 | |
| SCHEMBL14645946 | 0.90 | TDO2 (0.32) | — | |
| SCHEMBL20165756 | 0.90 | PTGS2 (0.30) | PTGS2PTGS1 | |
| SCHEMBL29992354 | 0.90 | PTGS2 (0.30) | PTGS2PTGS1 | |
| SCHEMBL14645960 | 0.86 | PDE4B (0.34) | — | |
| SCHEMBL15931794 | 0.86 | — | — | |
| SCHEMBL21433858 | 0.83 | — | — | |
| SCHEMBL17409131 | 0.81 | — | — | |
| SCHEMBL20609994 | 0.81 | TDO2 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2746289-B1 | Catalysts | BOREALIS AG (AT) | 2017-09-27 | — | — | EP | disclosed |
| EP-2729479-B1 | CATALYSTS | BOREALIS AG (AT) | 2017-09-06 | — | — | EP | disclosed |
| US-9630980-B2 | Asymmetrical ligands | BOREALIS AG (AT) | 2017-04-25 | — | — | US | disclosed |
| US-9469699-B2 | Catalysts | BOREALIS AG (AT) | 2016-10-18 | — | — | US | disclosed |
| US-9469699-B2 | Catalysts | BOREALIS AG (AT) | 2016-10-18 | — | — | US | disclosed |
| US-20160024123-A1 | Asymmetrical Ligands | BOREALIS AG (AT) | 2016-01-28 | — | — | US | disclosed |
| US-20160024123-A1 | Asymmetrical Ligands | BOREALIS AG (AT) | 2016-01-28 | — | — | US | disclosed |
| US-20160002369-A1 | CATALYSTS | BOREALIS AG (AT) | 2016-01-07 | — | — | US | disclosed |
| US-20160002369-A1 | CATALYSTS | BOREALIS AG (AT) | 2016-01-07 | — | — | US | disclosed |
| US-9187583-B2 | Catalysts | BOREALIS AG (AT) | 2015-11-17 | — | — | US | disclosed |
| US-9187583-B2 | Catalysts | BOREALIS AG (AT) | 2015-11-17 | — | — | US | disclosed |
| US-20140221584-A1 | CATALYSTS | BOREALIS AG (AT) | 2014-08-07 | — | — | US | disclosed |
| US-20140221584-A1 | CATALYSTS | BOREALIS AG (AT) | 2014-08-07 | — | — | US | disclosed |
| WO-2014096164-A1 | CATALYSTS | BOREALIS AG (AT) | 2014-06-26 | — | — | WO | disclosed |
| EP-2746289-A1 | Catalysts | Borealis AG (AT) | 2014-06-25 | — | — | EP | disclosed |
| EP-2729479-A1 | CATALYSTS | Borealis AG (AT) | 2014-05-14 | — | — | EP | disclosed |
| WO-2013007650-A1 | CATALYSTS | BOREALIS AG (AT) | 2013-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160002369-A1 | CATALYSTS | SIGMAR1, SFN, AP3S1 | PTGS2 3592/4885PTGS1 4543/4885 |
| US-20160024123-A1 | Asymmetrical Ligands | CCRL2, AR, CCR2 | PTGS2 1902/4885PTGS1 3955/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.